Revvity Inc
RVTY
Company Profile
Business description
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
Contact
77 4th Avenue
WalthamMA02451
USAT: +1 781 663-6900
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
11,000
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.50 | 10.00 | 0.11% |
| CAC 40 | 8,152.82 | 21.67 | 0.27% |
| DAX 40 | 24,894.44 | 38.64 | -0.15% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,207.80 | 58.95 | 0.58% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,494.94 | 15.94 | -0.12% |
| S&P 500 | 6,978.60 | 28.37 | 0.41% |
| S&P/ASX 200 | 8,941.60 | 14.90 | 0.17% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |